- Home
- / Alimera Sciences
Alimera Sciences
Stock Price
$5.5
2024-09-18
Market Capitalization
$301.3 M
2024-09-18
Revenue
$80.8 M
FY, 2023
Alimera Sciences Summary
Company Summary
- Overview
- Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. It provides ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME).
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Alpharetta, GA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Rick Eiswirth, Director, President and Chief Executive Officer
Susan Caballa, Sr. Vice President, Regulatory & Medical Affairs
Brian Halak, Director
LocationsView all
5 locations detected
Alpharetta, GA HQ
United States
6120 Windward Pkwy #290
Berlin, Berlin
Germany
21 Cicerostraße
Dublin 2, County Dublin
Ireland
block c, Fitzwilliam Business Centre, 77 Sir John Rogerson's Quay, Dublin Docklands
Lisboa, Lisboa
Portugal
Avenida D. João II, 50 Edificio, R. do Mar Vermelho
Hampshire
United Kingdom
Wellesley Rd
Alimera Sciences Financials
Summary Financials
- Revenue (Q2, 2024)
- $27.0M
- Gross profit (Q2, 2024)
- $23.2M
- Net income (Q2, 2024)
- ($3.3M)
- Cash (Q2, 2024)
- $10.8M
- EBIT (Q2, 2024)
- ($77.0K)
- Enterprise value
- $360.2M